中广核核技术发展股份有限公司（以下简称"中广核技"）推进多年的质子医疗业务获得公司控股股东的 助力。 据中广核技6月10日披露的公告，公司控股股东中广核核技术应用有限公司（以下简称"核技术公司"） 拟以现金方式向公司全资子公司中广核医疗科技（绵阳）有限公司（以下简称"绵阳医疗"）增资5亿 元，用于绵阳医疗开展质子医疗的研发项目和未来的经营发展。 浙大城市学院副教授、中国城市专家智库委员会常务副秘书长林先平在接受《证券日报》记者采访时表 示："控股股东的增资表明了对公司该项业务的重视和支持，有助于该项业务的顺利推进。" 中广核技是一家主要聚焦于非动力核技术应用领域的上市企业。公司主营业务包括电子加速器研发与制 造、电子束处理特种废物、辐照加工服务、新材料研发与制造以及医疗健康业务几大板块。 中广核技的医疗健康业务起步于2020年。当年，中广核技引进比利时IBA公司多室质子治疗技术，并在 四川绵阳建设质子医疗装备制造基地和医用同位素生产基地，全面推进该技术的国产化和自主化进程。 其中，质子医疗装备业务主要由绵阳医疗承载。 对于中广核技围绕非动力核技术布局医疗健康业务，深圳市优品投资顾问有限公司投资顾问李鹏岩在接 ...

Policy Developments - The Central Committee and State Council issued an opinion to improve the adjustment mechanism for the basic medical insurance drug catalog and to establish an innovative drug catalog for commercial health insurance [2] - The opinion aims to promote the sharing of high-quality medical resources and enhance the capacity of grassroots medical institutions [2] - The commercial health insurance sector is becoming a crucial lever for the high-quality development of commercial health insurance, helping to address the payment challenges for innovative drugs [3] Medical Device Approvals - DaAn Gene obtained a medical device registration certificate for six nucleic acid test kits for respiratory pathogens, expanding its product portfolio [5] - BGI Innovation received a medical device registration certificate for a human papillomavirus genotyping test kit, classified as Class III [6] - Shanghai Pharmaceuticals received approval for the production of Formoterol Fumarate inhalation solution, which is used for the maintenance treatment of chronic obstructive pulmonary disease [7] Corporate Transactions - Pilin Bio announced the resumption of trading after China National Pharmaceutical Group acquired 21.03% of its shares, changing the controlling shareholder [8] - China General Nuclear Power Corporation plans to inject 500 million yuan into its subsidiary for proton medical research and development [9] - Zhonghui Pharmaceutical completed two rounds of financing totaling nearly 50 million yuan, which will be used for the construction of a hollow microneedle medical device production base [10] Industry Developments - Dongxing Medical's subsidiary signed two contracts with Shanghai Jiao Tong University for synthetic biology technology development, totaling 6 million yuan [11] Regulatory Alerts - Huahai Pharmaceutical received a warning letter from the FDA regarding its production facility, which may affect future ANDA applications but will not significantly impact current performance [12]